Cellular Immunity Impaired Among Patients on Left Ventricular Assist Device for 6 Months

Annals of Thoracic Surgery

Volumn 85, Issue 5, 2008, Pages 1656-1661

  Kimball, Pam M ^a   Flattery, Maureen ^a   McDougan, Felecia ^a   Kasirajan, Vigneshwar ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; STAPHYLOCOCCUS ENTEROTOXIN B; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APOPTOSIS; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; HEART ASSIST DEVICE; HEART EJECTION FRACTION; HUMAN; MALE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION;

CROSS INFECTION; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HEART-ASSIST DEVICES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; INTERLEUKIN-10; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROSTHESIS DESIGN; REFERENCE VALUES; RETROSPECTIVE STUDIES; SURGICAL WOUND INFECTION; SURVIVAL RATE; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42949100806     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2008.01.050     Document Type: Article

References (27)

1. Martin J., Friesewinkel O., Benk C., Sorg S., Schultz S., and Beyersdorf F. Improved durability of the HeartMate XVE left ventricular assist device provides safe mechanical support up to 1 year but is associated with high risk of device failure in the second year. J Heart Lung Transplant 25 (2006) 384-390
2. Holman W.L., Park S.J., Long J.W., et al. Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant 23 (2004) 1359-1365
3. Kalya A.V., Tector A.J., Crouch J.D., et al. Comparison of Novacor and HeartMate vented electric left ventricular assist devices in a single institution. J Heart Lung Transplant 24 (2005) 1973-1975
4. Chinn R., Dembitsky W., Eaton L., et al. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J 51 (2005) 461-470
5. Bentz B., Hupcey J., Polomano R., and Boehmer J. A retrospective study of left ventricular assist device-related infections. J Cardiovasc Manag 15 (2004) 9-16
6. Kasirajan V., McCarthy P.M., Hoercher K.J., et al. Clinical experience with long-term use of implantable left ventricular assist devices: indications, implantation, and outcome. Semin Thorac Cardiovasc Surg 12 (2000) 229-237
7. Ankersmit H.J., Edwards N.M., Schuster M., et al. Quantitative changes in T cell populations after left ventricular assist device implantation. Circulation 100 Suppl (1999) II211-II215
8. Rothenburger M., Wilhelm M., Hammel D., et al. Immune response in the early postoperative period after implantation of a left ventricular assist device system. Transpl Proc 33 (2001) 1955-1957
9. Malani P.N., Dyke D.B., Pagani F.D., and Chenoweth C.E. Nosocomial infections in left ventricular assist device recipients. Clin Infect Dis 34 (2002) 1295-1300
10. Simon D., Fischer S., Grossman A., et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis 40 (2005) 1108-1115
11. Deng M.C., Erren M., Tjan T.D., et al. Left ventricular assist system support is associated with persistent inflammation and temporary immunosuppression. Thorac Cardiovasc Surg 47 (1999) 326-331
12. Itescu S., Andersmit J.H., Kocher A.A., and Schuster M.D. Immunobiology of left ventricular assist devices. Prog Cardiovasc Dis 43 (2000) 67-80
13. Clark A.L., Loebe M., Potapov E.V., et al. Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight. Eur Heart J 22 (2001) 2275-2283
14. Itescu S., and John R. Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications. Ann Thorac Surg 75 Suppl (2003) S58-S65
15. Kimball P.M., Shiffman M., and Verbeke S. Proliferative suppression and class I insufficiency on peripheral blood cells from hepatitis C patients overcome by exogenous cytokines or high dose mitogen. Clin Immunol 103 (2002) 317-323
16. Woitas R.P., Lechmann M., Jung G., Kaiser R., Sauerbruch T., and Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 159 (1997) 1012-1018
17. Trzonkowski P., Szmit E., Mysliwska J., and Mysliwski A. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. Clin Immunol 119 (2006) 307-316
18. hi regulatory cells in human peripheral blood. J Immunol 167 (2001) 1245-1253
19. Ankersmit H., Tugudea S., Spanier T., et al. Activation induced T cell death and immune dysfunction after implantation of left ventricular assist device. Lancet 354 (1999) 550-555
20. Schuster M., Kocher A., John R., et al. B cell activation and allosensitization after left ventricular assist device implantation is due to T cell activation and CD40 ligand expression. Hum Immunol 63 (2002) 211-220
21. Zaffe D., Bertoldi C., and Consolo U. Element release from titanium devices used in oral and maxillofacial surgery. Biomaterials 24 (2003) 1093-1099
22. Frisk P., Lindvall A., Hudecek R., and Lindh U. Decrease of trace elements in erythrocytes and plasma after removal of dental amalgam and other metal alloys. Biol Trace Elem Res 113 (2006) 247-259
23. Hallab N.J., Midecz K., Vermes C., Skipor A., and Jacobs J.J. Orthopaedic implant related metal toxicity in terms of human lymphocyte reactivity to metal-protein complexes produced from cobalt-base and titanium-base implant alloy degradation. Mol Cell Biochem 222 (2001) 127-136
24. Busuttil S.J., Drumm C., and Plow E.F. In vivo comparison of the inflammatory response induced by different vascular biomaterials. Vascular 13 (2005) 230-235
25. Ferreira M.E., de Lourdes Pereira M., Garcia e Costa F., Sousa J.P., and de Carvalho G.S. Comparative study of metallic biomaterials toxicity: a histochemical and immunohistochemical demonstration in mouse spleen. J Trace Elem Med Biol 17 (2003) 45-49
26. Kimball P.M., Elswick R., and Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-a therapy. J Med Virol 65 (2001) 510-516
27. Ormandy L.A., Hillemann T., Wedemeyer H., Manns M.P., Greten T.F., and Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65 (2005) 2457-2464